Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0BBWPI)
| ADC Name |
SYS6023
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
SYS6023; SYSY2105; SYY2007
Click to Show/Hide
|
|||||
| Organization |
CSPC Pharmaceutical Group (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Antibody Name |
Anti-HER3 mAb
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-3 (HER3)
|
Antigen Info | ||||
| Payload Name |
Self-developed TOP1 inhibitor
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Enzymatic Catalysis
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Disease Name | Phase 1 | Phase 2 | Phase 3 | Approved |
|---|---|---|---|---|
| Lung cancer | ||||
| Breast cancer | ||||
| Ovarian cancer | ||||
| Unspecific solid tumor |